


## Data Sheet

<b>Product Name:</b>	Tavilemide
<b>Cat. No.:</b>	CS-7495
<b>CAS No.:</b>	263251-78-1
<b>Molecular Formula:</b>	C <sub>24</sub> H <sub>32</sub> N <sub>6</sub> O <sub>11</sub>
<b>Molecular Weight:</b>	580.54
<b>Target:</b>	Trk Receptor
<b>Pathway:</b>	Neuronal Signaling; Protein Tyrosine Kinase/RTK
<b>Solubility:</b>	H <sub>2</sub> O : 5 mg/mL (8.61 mM; adjust pH to 3-4 with HCl)



### BIOLOGICAL ACTIVITY:

Tavilemide is a selective, partial agonist of **TrkA**, or a nerve growth factor (NGF) mimetic. IC<sub>50</sub> & Target: TrkA<sup>[1]</sup> **In Vitro:** Tavilemide (MIM-D3) is a tyrosine kinase TrkA receptor agonist, which can be used to treat dry eye. Tavilemide is a proteolytically stable, cyclic peptidomimetic that has been shown to be a partial TrkA receptor agonist. Tavilemide demonstrates activities similar to NGF (but does not bind to the p75NTR receptor) and can potentiate the effects of suboptimal concentrations of NGF<sup>[1]</sup>.

### References:

[1]. Meerovitch K, et al. Safety and efficacy of MIM-D3 ophthalmic solutions in a randomized, placebo-controlled Phase 2 clinical trial in patients with dry eye. Clin Ophthalmol. 2013;7:1275-85.

### CAIndexNames:

Glycine, N-(2-hydroxy-5-nitrobenzoyl)-L-α-glutamyl-L-lysyl-L-homoseryl-, cyclic (1→3)-ether

### SMILES:

O=C(O)CC[C@H](N1)C(N[C@@H](CCCCN)C(N[C@H](C(NCC(O)=O)=O)CCOC2=CC=C([N+](O-)=O)C=C2C1=O)=O)=O

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 732-484-9848 Fax: 888-484-5008 E-mail: sales@ChemScene.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA